 |
|
Efavirenz-Induced Leukocytoclastic Vasculitis
Arch Intern Med. 2002;162:355-356.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Efavirenz is a nonnucleoside reverse transcriptase inhibitor with a
potent inhibitory activity against human immunodeficiency virus (HIV), which
has been confirmed in clinical trials. The most frequent adverse effects of
efavirenz have been symptoms related to the central nervous system, such as
dizziness, impaired concentration, insomnia, abnormal dreaming, and maculopapular
rash.1 In addition, other adverse skin reactions,
such as hypersensitivity syndrome and photosensitivity reaction, have been
attributed to efavirenz use.2
To our knowledge, cutaneous vasculitis has not been associated with
efavirenz use. We have recently cared for a patient who developed leukocytoclastic
vasculitis soon after beginning treatment with efavirenz.
Report of a Case
A 44-year-old man infected with HIV, who has never had opportunistic
infections, started antiretroviral therapy in 1995 with zidovudine monotherapy
that was changed 18 months later to combination antiretroviral therapy with
stavudine, lamivudine, and indinavir sulfate. In October 2000, simplification
of treatment was proposed by switching from indinavir to efavirenz. At . . . [Full Text of this Article]
Comment
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection
Borras-Blasco et al.
J Antimicrob Chemother 2008;62:879-888.
ABSTRACT
| FULL TEXT
Evaluation and Treatment of the Human Immunodeficiency Virus-1--Exposed Infant
King et al.
Pediatrics 2004;114:497-505.
ABSTRACT
| FULL TEXT
|
